On June 9, 2021, Cymedica Orthopedics announced that the U.S. Food and Drug Administration (FDA) has approved the regulatory application for Intellihab’s system for the relief of knee osteoarthritis pain.
The Intellihab system is a treatment and digital health ecosystem for use at home that introduces a non-opioid, non-invasive treatment option for patients seeking relief of knee osteoarthritis pain while being able to remotely provide real-time progress data to physicians.
Symptomatic osteoarthritis of the knee, also known as degenerative joint disease, not only affects the health and mobility of tens of millions of patients, but also may cause a huge social and economic burden in the future.
More than half of patients are younger than 65 years old and can suffer from the disease for decades after diagnosis.
Treatment options for the condition are currently limited, with the most common treatments being invasive surgery (regular injections of cortisone or hyaluronic acid, and joint reconstruction or replacement), or the use of over-the-counter painkillers and opioids, which are potentially addictive.
The Intellihab system relies on neuromuscular electrical stimulation therapy.
This involves sending electrical impulses directly to the motor nerves that supply the quadriceps femoris, causing the muscles to contract in the same way they would in squats or other exercises.
These contractions strengthen the muscles, which in turn takes the pressure off the patient’s knee, reducing pain.
Patients can conduct regular neuromuscular stimulation therapy at home using an electrical stimulation system connected to the app, and manage and control their own muscle stimulation therapy through the app.
In addition, their doctors will be able to remotely monitor their use and disease progression.